Kameel D. Farag Insider Profile
4 Followers
Kameel D. Farag, Interim CFO at Akari Therapeutics, holds 23.31K shares in Akari Therapeutics (Ticker: AKTX), holds ― shares in BioVie (Ticker: BIVI).
Kameel D. Farag has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Kameel D. Farag holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Kameel D. Farag
Kameel D. Farag's Trading History
Akari Therapeutics
Aug 19, 2026
Interim CFO
Uninformative Buy
12.99K
$213.51K
BioVie
―
Director
―
―
List of latest transactions for each holding click on a transaction to see Kameel D. Farag's performance on stock
You May Also Like
Kameel D. Farag insider profile FAQ
What is the percentage of profitable transactions made by Kameel D. Farag?
The percentage of profitable transactions made by Kameel D. Farag is ―.
What is the average return per transaction made by Kameel D. Farag?
The average return per transaction made by Kameel D. Farag is ―.
What stocks does Kameel D. Farag hold?
Kameel D. Farag holds: AKTX, BIVI stocks.
What was Kameel D. Farag’s latest transaction?
Kameel D. Farag latest transaction was an Uninformative Buy of $12.99K.
What was Kameel D. Farag's most profitable transaction?
Kameel D. Farag’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Kameel D. Farag's role in Akari Therapeutics?
Kameel D. Farag's role in Akari Therapeutics is Interim CFO.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.